Mrgreen from the other board says this: I'm now more confident than ever this is headed to the triple digits. In today's day and age, turning $150m into several billion in value is very doable if you're in the fintech space. Even the haters will hand the longs that this was perfectly timed. Normally with a shelf offering, it's a bad thing. In biotech, if you get a shelf prior to drug approval it means your investment timing was off. But for this kind of stock, it's tantamount to a very low cost IPO. Self offering proceeds don't have that fat investment banker's fee. This kind of deal is very, very shareholder friendly. With the volume we've had lately I doubt it will be a big deal to get $150M sold quickly. I love how PaySign won't play by WallStreet's rules yet the street still loves it. Up-listing instead of IPO. Shelf offering instead of IPO. No debt. Minimal PR. No ringing of the Nasdaq opening bell. Kind of reminds you of an early Berkshire or something, does it not?
News 
Market Data 
Discover 
